Tissue modification systems and methods and signal generators for use therewith
By combining LV and HV signal generators and controllers, the HV signal is adjusted according to the impedance estimates of the patient's tissue, the problem of inconsistent treatment results caused by individual differences in pulsed electric field treatment is solved, and more efficient and safe tissue treatment is achieved.
Patent Information
- Application Number
- CN202380028256.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-19
- Publication Date
- 2024-11-01
AI Technical Summary
In pulsed electric field treatment, due to differences between patients and between treatment courses, the treatment effect is significantly different. It is difficult for the prior art to effectively control voltage and current to adapt to individual differences.
Using a tissue therapy system including an LV signal generator and an HV signal generator, the voltage and current of the HV signal are adjusted according to the impedance estimate of the patient's tissue by combining the LV tissue impedance measurement signal and the HV tissue treatment signal, so as to achieve More personalized treatment.
By dynamically adjusting the voltage and current of the HV signal, the treatment signal can be transmitted more effectively, improving the consistency and efficacy of treatment, and reducing the risk of overtreatment and arc discharge.
Smart Images

Figure CN118891014A_ABST
Abstract
Description
Technical Field
[0001] Certain embodiments of the present technology relate to signal generators for use in therapeutic systems (e.g., tissue modification systems), and therapeutic systems including signal generators. Certain embodiments of the present technology also relate to methods used by and / or with signal generators, and / or methods used by therapeutic systems including signal generators.
[0002] priority
[0003] This application claims priority to U.S. patent application Ser. No. 17 / 587,844, filed on January 28, 2022, which is incorporated herein by reference. Background Art
[0004] Pulsed electric field therapy (PEF) can be used to deliver high voltage, short duration pulses to affect diseased tissue in various endoluminal structures (airways, gastrointestinal tract), unresectable tissue targets (liver, pancreas, lung, kidney), or cancerous solid tumors. However, PEF therapy with the delivered voltage as the target treatment index may result in significant differences in patient outcomes. This is due, at least in part, to differences between patients and between treatment courses, where a treatment course refers to a period of time during which a patient is treated under generally consistent exogenous factors. Thus, differences between treatment courses may include different patients or different patient conditions. Differences between patients and between treatment courses may be caused by differences in a variety of factors, including differences in hydration, sex, blood pressure, placement of dispersive electrode pads, skin thickness, hair at the dispersive electrode site, materials delivered to the patient topically or systemically, and many other factors. It would be very beneficial if PEF therapy, and HV tissue therapy more generally, could be controlled to account for differences between patients and between treatment courses. Summary of the invention
[0005] Disclosed herein are tissue treatment systems and methods that can be used to deliver HV tissue treatment signals in a manner that accounts for inter-patient variability as well as inter-treatment variability.
[0006] In certain embodiments, the tissue treatment system includes an LV signal generator, an HV signal generator, and a controller. The LV signal generator is used to generate an LV tissue impedance measurement signal, and the HV signal generator is used to generate an HV tissue treatment signal, the voltage of which is at least five times the voltage of the LV tissue impedance measurement signal. The controller controls when the HV tissue treatment signal generated by the HV signal generator is transmitted to the patient tissue through the active electrode and the return electrode, and when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue through the active electrode and the return electrode. The LV tissue impedance measurement signal is used to estimate the impedance of the patient tissue, which is used to control the voltage and / or current of the HV tissue treatment signal.
[0007] According to certain embodiments, the tissue treatment signal further includes a current sensing circuit configured to measure a current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal generated using the LV signal generator is transmitted to the patient tissue. In certain such embodiments, the controller is further configured to generate an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit, and to control the voltage of the HV tissue treatment signal generated using the HV signal generator based on the estimate of the impedance of the patient tissue.
[0008] According to certain embodiments, the controller is configured to control the voltage of the HV tissue treatment signal generated using the HV signal generator based on an estimated value of the impedance of the patient tissue, so that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0009] According to certain embodiments, between each of a plurality of separate instances in which the HV signal generator is used to generate an HV tissue treatment signal for delivery to patient tissue, the controller is configured to cause the LV signal generator to generate an LV tissue impedance measurement signal for delivery to the patient tissue. The controller is further configured to generate an updated estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal delivered to the patient tissue and based on an updated measurement of the current delivered to the patient tissue measured using the current sensing circuit. The controller is further configured to, in response to the updated estimate of the impedance of the patient tissue being different from an immediately previous estimate of the impedance of the patient tissue, adjust the voltage of the HV tissue treatment signal generated using the HV signal generator so that when the HV tissue treatment signal is next delivered to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0010] According to some embodiments, the LV signal generator includes a LV power supply, and the HV signal generator includes a HV power supply that is different from the LV power supply of the LV signal generator. In some such embodiments, the LV signal generator includes a LV waveform shaping circuit connected between the LV power supply and the active electrode and the return electrode, and the HV signal generator includes a HV waveform shaping circuit that is different from the LV waveform shaping circuit and connected between the HV power supply and the active electrode and the return electrode. Alternatively, the LV signal generator and the HV signal generator share the same waveform shaping circuit.
[0011] According to certain embodiments, the tissue treatment system also includes an LV current sensing circuit, which is configured to measure the current transmitted to the patient tissue via the active electrode when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue. The tissue treatment system also includes an HV current sensing circuit, which is different from the LV current sensing circuit and is configured to measure the current transmitted to the patient tissue via the active electrode when the HV tissue treatment signal generated by the HV signal generator is transmitted to the patient tissue. In certain such embodiments, the controller is also configured to generate an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the LV current sensing circuit. The controller is also configured to set the voltage of the HV tissue treatment signal generated using the HV signal generator based on the estimate of the impedance of the patient tissue. In addition, the controller is configured to adjust the voltage of the HV tissue treatment signal generated using the HV signal generator based on the current measured by the HV current sensing circuit.
[0012] According to certain embodiments, a tissue treatment system includes a pair of electrodes, a plurality of capacitors, a power supply, a waveform shaping circuit, and a controller. The power supply is configured to charge the plurality of capacitors. The waveform shaping circuit is coupled between the plurality of capacitors and the pair of electrodes. The controller is configured to couple a first subset of the capacitors to the waveform shaping circuit during a first time period when an LV tissue impedance measurement signal is transmitted to patient tissue via the pair of electrodes, and couple a second subset of the capacitors to the waveform shaping circuit during a second time period when an HV tissue treatment signal is transmitted to patient tissue via the pair of electrodes. In certain such embodiments, a voltage of the HV tissue treatment signal is at least five times a voltage of the LV tissue impedance measurement signal. The first subset of capacitors includes at least one of the plurality of capacitors. The second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset.
[0013] According to certain embodiments, a first subset of power supplies, waveform shaping circuits, and capacitors are components of an LV signal generator for generating an LV tissue impedance measurement signal. A second subset of power supplies, waveform shaping circuits, and capacitors are components of an HV signal generator for generating an HV tissue therapy signal. In such embodiments, the power supplies and waveform shaping circuits are shared by the LV signal generator and the HV signal generator.
[0014] According to certain embodiments, a pair of electrodes includes an active electrode and a return electrode, and the tissue treatment system further includes a current sensing circuit configured to measure a current transmitted to the patient tissue via the active electrode when the LV tissue impedance measurement signal is transmitted to the patient tissue. In certain such embodiments, the controller is further configured to generate an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit. In addition, the controller is configured to control the voltage of the HV tissue treatment signal based on the estimate of the patient tissue impedance.
[0015] According to certain embodiments, the method includes the following steps: (a) generating an LV tissue impedance measurement signal and transmitting the LV tissue impedance measurement signal to patient tissue through an active electrode and a return electrode; (b) measuring the current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal is transmitted to the patient tissue; (c) generating an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the measured current; and (d) generating an HV tissue treatment signal and transmitting the HV tissue treatment signal through the active electrode and the return electrode, wherein the voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal, and wherein generating the HV tissue treatment signal includes controlling the voltage of the HV tissue treatment signal based on the estimate of the impedance of the patient tissue.
[0016] According to certain embodiments, steps (a), (b), (c) and (d) are performed in sequence, and after being performed in that sequence, steps (a), (b), (c) and (d) are repeated in that sequence, such that an updated estimate of the impedance of the patient tissue is generated when step (c) is repeated, and such that the voltage of the HV tissue treatment signal is controlled based on the updated estimate of the impedance of the patient tissue when step (d) is repeated.
[0017] According to some embodiments, steps (a), (b), (c), and (d) are performed in the order described, and after being performed in that order, steps (a), (b), and (c) are repeated in that order to generate an updated estimate of the impedance of the patient tissue. In some such embodiments, the method further includes determining whether treatment of the patient tissue is sufficient or whether additional treatment should be performed on the patient tissue in an additional instance of step (d) based on the updated estimate of the impedance of the patient tissue.
[0018] According to certain embodiments, when additional treatment is to be performed on the patient tissue in an additional instance of step (d), generating the HV treatment signal in the additional instance of step (d) includes controlling the voltage of the HV tissue treatment signal based on an updated estimate of the impedance of the patient tissue.
[0019] According to certain embodiments, generating the LV tissue impedance measurement signal in step (a) is performed using an LV signal generator, and generating the HV tissue therapy signal in step (c) is performed using an HV signal generator different from the LV signal generator.
[0020] According to certain embodiments, the method further comprises charging a plurality of capacitors using a power source and shaping the LV tissue impedance measurement signal and the HV tissue therapy signal using a waveform shaping circuit coupled between the plurality of capacitors and the active electrode and the return electrode. In certain such embodiments, generating and transmitting the LV tissue impedance measurement signal in step (a) comprises coupling a first subset of capacitors to the waveform shaping circuit during a first time period, and generating and transmitting the HV tissue therapy signal in step (c) comprises coupling a second subset of capacitors to the waveform shaping circuit during a second time period. The first subset of capacitors comprises at least one of the plurality of capacitors, and the second subset of capacitors comprises at least one of the plurality of capacitors and is different from the first subset.
[0021] This summary is not intended to be a complete description of embodiments of the present technology. Other features and advantages of embodiments of the present technology will become apparent from the following description, in which preferred embodiments have been described in detail in conjunction with the accompanying drawings and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1A An exemplary treatment system for treating a patient is shown.
[0023] Figure 1B It was originally Figure 1A Schematic diagram of an embodiment of the treatment system introduced in.
[0024] Figure 2 yes Figure 1A and Figure 1B An exemplary circuit diagram of an output signal generator circuit of the signal generator introduced in .
[0025] Figure 3 An example of a biphasic therapy signal waveform dictated by an energy delivery algorithm is shown.
[0026] Figure 4 Shown by Figure 2 A controller of the circuit described herein generates a signal that is used to control a switch to generate a biphasic therapy signal.
[0027] Figure 5A According to an embodiment of the present technology ( Figure 1A and Figure 1B High-level block diagram of the output signal generator introduced in .
[0028] Figure 5B is a high-level block diagram of an output signal generator according to another embodiment of the present technology.
[0029] Figure 5C is a high-level block diagram of an output signal generator according to yet another embodiment of the present technology.
[0030] Figure 5D is a high-level block diagram of an output signal generator according to yet another embodiment of the present technology.
[0031] Figure 6 is a high-level flow chart used to describe methods according to certain embodiments of the present technology. DETAILED DESCRIPTION
[0032] Certain embodiments of the present invention relate to signal generators for use in therapeutic systems (such as, but not limited to, tissue modification systems). Figure 1A An exemplary treatment system 100 for treating a patient is shown. Figure 1B yes Figure 1A Schematic diagram of an embodiment of a therapeutic system is shown in FIG. In this embodiment, system 100 includes a therapeutic energy delivery device 102 (e.g., a catheter) that can be connected to a signal generator 104. Signal generator 104 may be more simply referred to herein as generator 104. Figure 1A, the instrument 102 is shown as having an elongated shaft 106 with at least one transmission electrode 108 near its distal end 124 and a handle 110 at its proximal end 128. The instrument 102 can be connected to a generator 104 as part of the treatment system 100. The connection of the instrument 102 to the generator 104 provides electrical energy to the transmission electrode 108, among other functions. In this embodiment, the transmission electrode 108 is shown as a "solid tip" electrode having a cylindrical shape with a continuous surface on its distal side. In some embodiments, the cylindrical distal end face has a diameter of about 2-3 mm and a length along the shaft 106 of about 1 mm, 2 mm, 1-2 mm, 3 mm, 4 mm, 3-4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, etc. It will be appreciated that such electrodes are typically hollow, but are referred to as solid for appearance reasons. In some embodiments, the total length of the catheter 102 is 50-150 cm, preferably 100-125 cm, and more preferably 110-115 cm. Similarly, in some embodiments, the outer diameter of the catheter 102 is 7 Fr, preferably 3-15 Fr, preferably 4-12 Fr, and more preferably 7-8.5 Fr. The deflection of the shaft 106 can be achieved by a variety of mechanisms, including a pull wire extending to the handle 110. Therefore, the handle 110 is used to manipulate the catheter 102, especially the distal end during delivery and treatment. Energy is provided to the catheter 102 by a cable 130 that can be connected to the generator 104, thereby providing energy to the transmission electrode 108. In some embodiments, the handle 110 is removable, for example by pressing a handle removal button. The energy transmission electrode 108 may also be referred to as an active electrode 108 herein. It will be appreciated that various types of visualization can be used, including (to name a few) angiography (optionally including markers), computed tomography, optical coherence tomography, ultrasound, and direct video visualization.
[0033] The pulsed electric field (PEF) is provided by the generator 104 and transmitted to the tissue by the transmission electrode 108 placed on or near the target tissue area. It is understood that in some embodiments, the transmission electrode 108 is positioned to contact with a conductive substance, which is also in contact with the target tissue. Such solutions may include isotonic or hypertonic solutions. These solutions may also include auxiliary materials, such as chemotherapy or calcium, to further enhance the therapeutic effect of focal treatment and potential regional infiltration areas of the target tissue type. Then, high-voltage, short-duration biphasic electrical pulses are transmitted through the electrode 108 near the target tissue. These electrical pulses are provided by at least one energy transmission algorithm 152. In some embodiments, each energy transmission algorithm 152 specifies a signal with a waveform, which includes a series of energy packets, wherein each energy packet includes a series of high-voltage pulses. In such an embodiment, the algorithm 152 specifies the parameters of the signal, such as energy amplitude (e.g., voltage) and the duration of energy application, which includes the number of packets, the number of pulses in the packet, and the fundamental frequency of the pulse sequence. Other parameters may include switching time between polarities in the biphasic pulse, dead time between biphasic cycles, and rest time between packets, which are described in more detail below. There may be a fixed rest period between packets, or the packets may be gated to the cardiac cycle and thus vary with the patient's heart rate. There may be a deliberately varying rest period algorithm between packets, or no rest period may be applied. Feedback loops based on sensor information and automatic shut-off specifications may be included, etc.
[0034] It is understood that in various embodiments, the treatment catheter 102 includes various specialized features. For example, in some embodiments, the catheter 102 includes a mechanism for measuring the contact force applied by the catheter tip to the patient's heart wall in real time during the operation. In some embodiments, the mechanism is included in the shaft 106 and includes a three-axis optical force sensor using white light interferometry. By monitoring and modifying the applied force throughout the operation, the user can better control the catheter 102, thereby producing a more continuous and effective lesion. It is also possible to use other types of contact force sensors and are within the scope of the embodiments described herein.
[0035] In this embodiment, the therapeutic energy delivery device 102 can be connected to the generator 104 and the dispersive electrode 140 applied externally to the patient's skin. Therefore, in this embodiment, monopolar energy delivery is achieved by providing energy between the energy delivery electrode 108 located near the distal end of the device 102 and the dispersive electrode 140. The dispersive electrode 140 is also referred to herein as the return electrode 140. However, it should be understood that bipolar energy delivery and other arrangements can be used instead. When bipolar energy delivery is used, the therapeutic energy delivery device 102 can be different in overall design, such as including multiple energy delivery electrodes 108, or can look similar in overall design, such as including a single energy delivery electrode 108 configured to work in a bipolar manner. In some embodiments, the return electrode 140 is an implanted electrode, such as an implanted electrode located on the catheter 102 or sheath, but is not limited thereto. In some cases, bipolar energy delivery allows the use of lower voltages to achieve a therapeutic effect compared to monopolar energy delivery. In a bipolar configuration, the positive and negative electrodes are close enough to provide a therapeutic effect at and between the electrodes. This can extend the therapeutic effect to a larger, more superficial surface area than monopolar, thus requiring a lower voltage to achieve a therapeutic effect. Likewise, this lower voltage can be used to reduce penetration depth. Additionally, if the voltage delivered is low enough to avoid trapping cardiomyocytes, the lower voltage requirement can avoid the need for cardiac synchronization in certain circumstances.
[0036] In this embodiment, the generator 104 includes a user interface 150, one or more energy delivery algorithms 152, a processor 154, a data storage / retrieval unit 156 (e.g., a memory and / or a database), and an output signal generator circuit 158 that generates and / or stores energy to be delivered and produces a desired waveform for the energy to be delivered. In some embodiments, one or more capacitors are used for energy storage / delivery, but any other suitable energy storage element may be used. In some embodiments, various switches are used to generate the desired waveform for the energy to be delivered. In addition, one or more communication ports 167 may be included.
[0037] In some embodiments, the generator 104 includes three subsystems: 1) a high energy storage system, 2) a high voltage, intermediate frequency switching amplifier, and 3) a system controller, firmware, and user interface. The system controller includes a cardiac synchronization trigger monitor that allows the pulse energy output to be synchronized with the patient's heart rhythm. The generator receives an alternating current (AC) power source to power multiple direct current (DC) power sources. The controller of the generator can cause the DC power source to charge the high energy capacitor storage group before initiating energy delivery. When the therapeutic energy delivery is initiated, the controller of the generator, the high energy storage group, and the biphasic pulse amplifier can operate simultaneously to produce a high voltage, intermediate frequency output.
[0038] It should be appreciated that a variety of generator electrical architectures may be employed to implement energy delivery algorithms. Specifically, in some embodiments, an advanced switching system is used that is capable of directing pulsed electric field circuits from the same energy storage and high voltage delivery system to energy delivery electrodes separately. In addition, generators used in advanced energy delivery algorithms that employ rapidly changing pulse parameters (e.g., voltage, frequency, etc.) or multiple energy delivery electrodes may utilize modular energy storage and / or high voltage systems, thereby facilitating highly customizable waveforms and geographic pulse delivery paradigms. It should also be appreciated that the electrical architectures described above are merely examples, and that systems that deliver pulsed electric fields may or may not include additional switching amplifier components.
[0039] The user interface 150 may include a touch screen and / or more traditional buttons to allow the operator to enter patient data, select a treatment algorithm (e.g., energy delivery algorithm 152), initiate energy delivery, view records stored on a storage / retrieval unit 156, and / or otherwise communicate with the generator 104. The user interface 150 may include a voice activation mechanism to enter patient data, or may communicate with other devices in the suite to control the generator 104 via a secondary separate user interface.
[0040] In some embodiments, the user interface 150 is configured to receive operator-defined inputs. The operator-defined inputs may include the duration of energy delivery, one or more other timing aspects of the energy delivery pulses, power and / or operating mode, or a combination thereof. Example operating modes may include (but are not limited to): system startup and self-test, operator input, algorithm selection, pre-treatment system status and feedback, tissue impedance measurement, energy delivery, display or feedback after energy delivery, treatment data review and / or download, software update, or any combination or sub-combination thereof. According to certain embodiments, the user interface 150 displays information to a physician or technician or other user during automatic treatment delivery, wherein all of the above-mentioned dosage parameters (e.g., energy delivery duration, one or more other timing aspects of the energy delivery pulses, power and / or operating mode, or a combination thereof) may be preset. The user interface 150 may also be used to provide system status after one or more self-tests, and may provide a method for the user to confirm system status information. The user interface 150 may also be used to select or otherwise specify a target current and / or target voltage for treatment.
[0041] In some embodiments, the system 100 also includes a mechanism for acquiring an electrocardiogram (ECG), such as an external cardiac monitor 170. An exemplary cardiac monitor is available from AccuSync Medical Research Corporation. In some embodiments, the external cardiac monitor 170 is operably connected to the generator 104. The cardiac monitor 170 can be used to continuously acquire ECG signals. An external electrode 172 can be applied to the patient to acquire the ECG. The generator 104 analyzes one or more cardiac cycles and identifies the beginning of a time period in which energy can be safely applied to the patient, thereby providing the ability to synchronize energy delivery with the cardiac cycle. In some embodiments, the time period is within a few milliseconds of the R wave (ECG QRS complex) to avoid inducing arrhythmias, which may occur if energy pulses are transmitted on the T wave. It should be recognized that this cardiac synchronization is typically used when using unipolar energy delivery, but it can be used as part of other energy delivery methods.
[0042] In some embodiments, processor 154 modifies and / or switches between energy delivery algorithms, monitors energy delivery and any sensor data, and reacts to the monitored data via a feedback loop, among other activities. In some embodiments, processor 154 is configured to execute one or more algorithms for operating a feedback control loop based on one or more measured system parameters (e.g., current), one or more measured tissue parameters (e.g., impedance), and / or a combination thereof.
[0043] The data storage / retrieval unit 156 stores data, such as data related to the treatment being administered, and can optionally download the data by connecting a device (e.g., a laptop or thumb drive) to the communication port. In some embodiments, the device has local software for directing the download of information (e.g., instructions stored on the data storage / retrieval unit 156 and executable by the processor 154). In some embodiments, the user interface 150 allows the operator to select to download the data to a device and / or system, such as, but not limited to, a computer device, a tablet computer, a mobile device, a server, a workstation, a cloud computing device / system, and / or the like. The communication port can allow wired and / or wireless connections, can allow data downloads (as just described), and can also allow data uploads, such as uploading custom algorithms or providing software updates.
[0044] The data storage / retrieval unit 156 may be, for example, a random access memory (RAM), a memory buffer, a hard drive, a database, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), a flash memory, etc. The data storage / retrieval unit 156 is capable of storing instructions to enable the processor 154 to perform modules, processes, and / or functions associated with the system 100.
[0045] In some embodiments, the data storage / retrieval unit 156 includes a computer storage product having a non-transitory computer readable medium (also referred to as a non-transitory processor readable medium) having instructions or computer code thereon for performing various computer-implemented operations. A computer readable medium (or processor readable medium) is non-transitory because it does not itself include transient propagating signals (e.g., propagating electromagnetic waves that carry information on a transmission medium such as space or a cable). The medium and computer code (also referred to as code) may be designed and constructed for a specific purpose or purposes. Examples of non-transitory computer readable media include, but are not limited to: magnetic storage media such as hard disks, floppy disks, and magnetic tapes; optical storage media such as compact discs / digital video discs (CD / DVD), compact disc read-only memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical discs; carrier signal processing modules; and hardware devices specifically constructed to store and execute program code, such as ASICs, programmable logic devices (PLDs), read-only memories (ROMs), and random access memory (RAM) devices. Other embodiments described herein relate to computer program products, which may include, for example, instructions and / or computer code as described herein.
[0046] Examples of computer code include, but are not limited to, microcode or microinstructions, machine instructions (e.g., generated by a compiler), code for generating network services, and files containing high-level instructions executed by a computer using an interpreter. For example, an imperative programming language (e.g., C, Fortran, etc.), a functional programming language (Haskell, Erlang, etc.), a logical programming language (e.g., Prolog), an object-oriented programming language (e.g., Java, C++, etc.), or other suitable programming languages and / or development tools may be used to implement the embodiments. Other examples of computer code include, but are not limited to, control signals, encryption codes, and compression codes.
[0047] In some embodiments, the system 100 may be communicatively coupled to a network, which may be any type of network, such as a local area network (LAN), a wide area network (WAN), a virtual network, a telecommunications network, a data network, and / or the Internet, implemented as a wired network and / or a wireless network. In some embodiments, any or all communications may be protected using any suitable type and / or method of secure communications (e.g., secure socket layer (SSL)) and / or encryption techniques. In other embodiments, any or all communications may not be protected.
[0048] Figure 1B It was originally Figure 1A Schematic diagram of an embodiment of the treatment system 100 described in . In this embodiment, a dispersive (neutral) or return electrode 140 is operably connected to the generator 104 and fixed to the patient's skin to provide a return path for the energy delivered by the device 102. The energy delivery device 102 includes one or more energy delivery electrodes 108, one or more sensors 160, one or more imaging modalities 162, one or more buttons 164 and / or positioning mechanisms 166 (for example, but not limited to, a lever and / or dial on a handle with a pull wire, a telescoping tube, a sheath and / or the like), and one or more energy delivery (active) electrodes 108 are in contact with the tissue. In some embodiments, a foot switch 168 is operably connected to the generator 104 and is used to initiate energy delivery. The dispersive electrode 140 may also be referred to herein as a neutral electrode 140, a return electrode 140, or more simply as an electrode 140.
[0049] As previously described, the user interface 150 may include a touch screen and / or more conventional buttons to allow the operator to enter patient data, select a treatment algorithm 152, initiate energy delivery, view records stored on the storage / retrieval unit 156, or otherwise communicate with the generator 104. The processor 154 manages and executes the energy delivery algorithm, monitors the energy delivery and any sensor data, and reacts to the monitoring data through a feedback loop. The data storage / retrieval unit 156 stores data related to the treatment being administered, and the data may be downloaded by connecting a device (e.g., a laptop or thumb drive) to the communication port 167.
[0050] The instrument 102 is operably connected to the generator 104 and / or a separate imaging screen 180. The imaging modality 162 can be incorporated into the instrument 102, or used with or in conjunction with the instrument 102. Alternatively or additionally, a separate imaging modality or device 169 can be used, such as a commercially available system (e.g., a bronchoscope). The separate imaging device 169 can be mechanically, operatively, and / or communicatively coupled to the instrument 102 using any suitable mechanism.
[0051] Figure 2 In the above Figure 1A and Figure 1B An exemplary circuit diagram of an embodiment of the output signal generator circuit 158 of the signal generator 104 is presented in the discussion of FIG. Figure 2 , the output signal generator circuit 158 is shown to include a high voltage (HV) power supply 202, a controller 203, an HV capacitor 206, a leakage resistor 207, a waveform shaping circuit 208, a voltage sensing circuit 210, a voltage sensing circuit 212, and a current sensing circuit 214. As will be appreciated by one of ordinary skill in the art, the output signal generator circuit 158 may include additional circuitry not shown. For example, a step-up transformer, a filter, and / or a DC blocking capacitor may be optionally coupled between the output nodes (labeled OUT1 and OUT2) of the waveform shaping circuit 208 and the active electrode 108 and the return electrode 140. Such a step-up transformer may be used to step up the voltage signal generated between the output nodes (OUT1 and OUT2) of the waveform shaping circuit 208 to a desired level, as well as to isolate the HV power supply 202 and the waveform shaping circuit 208 from the electrodes 108, 140. Such a filter may be, for example, an RC snubber circuit comprising a resistor and a capacitor connected in series between electrode 108 and electrode 140, which may be used to filter out high frequency transients or ringing that may be caused by the leakage inductance of the transformer. Such a DC blocking capacitor may be used to prevent low frequency or DC current from inadvertently flowing through the patient's tissue.
[0052] Still refer to Figure 2, the HV power supply 202 is configured to selectively provide a high voltage DC signal that is used to charge the HV capacitor 206 to a desired voltage level. In some embodiments, the voltage sensing circuit 210 can be used to determine when the HV capacitor 206 is charged to a desired voltage level, but this is not necessarily the case. The HV power supply 202 may include, for example, an AC / DC converter that receives an alternating current (AC) power source and outputs a direct current (DC) signal. The HV power supply 202 may also include a step-up or step-down regulator that receives the output of the AC / DC converter and converts the output of the AC / DC converter to a desired voltage level and maintains the voltage level at a desired level. As will be understood by those of ordinary skill in the art, the HV power supply 202 may include additional and / or alternative circuits. The switch Sp is used to selectively connect the HV power supply 202 to the HV capacitor 206. In addition to (or in addition to) using the switch Sp to control whether the HV power supply 202 will charge the HV capacitor 206, the output of the HV power supply 202 may be selectively enabled and disabled by the controller 203, thereby selectively controlling whether the HV power supply 202 charges the HV capacitor 206 at any given time. Therefore, when the controller 203 is able to selectively enable and disable the output of the HV power supply 202, the switch Sp may be selectively eliminated.
[0053] HV capacitor 206 includes one or more HV capacitors for storing energy used to generate a tissue treatment signal delivered to a patient via electrodes 108, 140 or some other electrodes. Depending on the specific implementation, HV capacitor 206 may be implemented using a group of capacitors connected in series and / or in parallel with each other.
[0054] The leakage resistor 207 is used to selectively release all or part of the energy stored in the HV capacitor 206 by selectively turning on (i.e., closing) the switch S_bleed. For example, when the controller 203 uses the voltage sensing circuit 210 to determine that the voltage stored in the HV capacitor 206 is higher than the desired level, the controller 203 can turn on (i.e., close) the switch S_bleed until the voltage stored in the HV capacitor 206 is reduced to the desired level, at which time the controller 203 can turn off (i.e., open) the switch S_bleed. The switch Sp and the switch S_bleed can be implemented using corresponding insulated gate bipolar transistors (IGBTs), another type of transistor, or a relay, respectively, but are not limited thereto. Depending on the specific implementation, the leakage resistor 207 can be implemented using a group of resistors connected in series and / or in parallel to each other. It is also possible not to include any leakage resistors, but to leak any excess voltage stored in the HV capacitor 206 into the patient's tissue.
[0055] The waveform shaping circuit 208 is shown to include current limiting resistors Ra1, Ra2, Rb1, and Rb2 and switches Sa1, Sa2, Sb1, and Sb2. The switches are controlled by the controller 203, which may be implemented by a processor (e.g., Figure 1A and Figure 1B The controller 203 may be implemented by a processor 154 in the circuit 158, a field programmable gate array (FPGA), or the like. According to some embodiments, each of the switches Sa1, Sa2, Sb1, and Sb2 is implemented using a corresponding insulated gate bipolar transistor (IGBT). As will be appreciated by those skilled in the art, when each switch is implemented using a corresponding IGBT, each switch may include or be associated with a corresponding IGBT driver (not shown). Each of the IGBT drivers may selectively turn on (i.e., close) or off (i.e., open) a corresponding IGBT-type switch in response to a signal received from the controller 203. The output nodes of the waveform shaping circuit 208 (these nodes are labeled as output 1 and output 2) are connected to the active electrode 108 and the return electrode 140, respectively. Alternatively, if the circuit 158 includes a step-up transformer, the output nodes of the waveform shaping circuit 208 labeled as output 1 and output 2 may be connected to the primary side of the transformer, while the active electrode 108 and the return electrode 140 may be connected to the secondary side of the transformer. Alternatively, the above switches may be implemented using other types of transistors.
[0056] Figure 3 An embodiment of a waveform 300 of a therapy signal prescribed by the energy delivery algorithm 152 is shown, where the waveform 300 may be generated by selectively turning on and off various switches Sa1, Sa2, Sb1, and Sb2 under the control of the controller 203. The waveform 300 may also be referred to as a biphasic therapy signal 300, or more simply, a therapy signal 300. Figure 3 , one packet 302 is shown. However, the waveform 300 may also include one or more additional packets (not shown), wherein pairs of packets are separated from each other by rest periods. In this embodiment, the packet 302 consists of a first biphasic cycle (including a first positive pulse peak 308 and a first negative pulse peak 310), a second biphasic cycle (including a second positive pulse peak 308' and a second negative pulse peak 310'), and an nth biphasic cycle (including an nth positive pulse peak 308" and an nth negative pulse peak 310"), where n is an integer greater than or equal to 3. The first biphasic pulse and the second biphasic pulse are separated by a dead time 312 (i.e., a pause) between each pulse. In this embodiment, the biphasic pulses are symmetrical, so that the set voltage 316p of the positive peak is the same as the set voltage 316n of the negative peak, but this is not necessarily the case. Here, the biphasic symmetrical wave is also a square wave, so that the amplitude and time of the positive voltage wave are approximately equal to the amplitude and time of the negative voltage wave, but this is not necessarily the case.
[0057] When a therapeutic signal is applied using a bipolar configuration, the portions of cells facing the negative voltage wave (e.g., airway wall cells) experience cellular depolarization in these areas, where regions of the cell membrane that are normally negatively charged briefly become positively charged. Conversely, the portions of the cells facing the positive voltage wave experience hyperpolarization, where the potential of regions of the cell membrane becomes extremely negative. When used to treat the airway walls of a patient's lungs, it will be appreciated that portions of the airway wall cells will experience opposite effects in each positive or negative phase of the biphasic pulse. For example, the portion of the cell membrane facing the negative voltage will experience depolarization, while the portion 180 degrees from that portion will experience hyperpolarization. In some embodiments, the hyperpolarized portion faces the dispersion or return electrode 140.
[0058] The HV tissue treatment signal described herein can be used for example to transmit treatment energy to certain parts of the patient's heart to provide tissue reconstruction, such as being transmitted to the entrance of the pulmonary vein when treating atrial fibrillation (AF). The specific anatomical position of the target includes the superior vena cava, the inferior vena cava, the right pulmonary vein, the left pulmonary vein, the right atrium, the right atrial appendage, the left atrium, the left atrial appendage, the right ventricle, the left ventricle, the right ventricular outflow tract, the left ventricular outflow tract, the ventricular septum, the left ventricular apex, the myocardial scar area, the myocardial infarction border area, the myocardial infarction channel, the ventricular endocardium, the ventricular endocardium, the papillary muscle and the Purkinje system, etc. The treatment is carried out at an independent position, or in a series of related treatments. Treatment types include establishing a left atrial apical line, a left atrial posterior / inferior line, posterior wall isolation, lateral mitral isthmus line, septal mitral isthmus line, left atrial appendage, right tricuspid isthmus (CTI), pulmonary vein isolation, superior vena cava isolation, Marshall vein, creating lesions using complex fragmented atrial potentials (CFAE), creating lesions using focal activation and rotor modulation (FIRM), and targeted ganglion ablation. Such tissue modification produces conduction blocks within the tissue to prevent the transmission of abnormal electrical signals. These devices, systems, and methods are typically used in an electrophysiology laboratory or controlled operating room equipped with fluoroscopy and advanced ECG recording and monitoring capabilities. Electrophysiologists (EPs) are the intended primary users of the system. Electrophysiologists will be supported by a trained staff of nurses, technicians, and possibly other electrophysiologists. In general, tissue modification systems include specialized catheters, high voltage waveform generators, and at least one different energy delivery algorithm.
[0059] The voltage used and considered may be the top of a square waveform, may be the peak of a sine waveform or sawtooth waveform, or may be the RMS voltage of a sine waveform or sawtooth waveform. In some embodiments, energy is delivered in a unipolar manner, and each high voltage pulse or set voltage 316 is between about 500V and 10,000V, particularly about 500V to 5000V, about 500V to 4000V, about 1000V to 4000V, about 2500V to 4000V, about 2000 to 3500, about 2000V to 2500V, about 2500V to 3500V, including all values and sub-ranges therebetween, and including about 500V, 1000V, 1500V, 2000V, 2500V, 3000V, 3500V, 4000V. In some embodiments, each high voltage pulse is in the range of about 1000V to 2500V, which can penetrate the airway wall W under a specific parameter combination to treat or affect shallow specific cells, such as epithelial cells. In some embodiments, each high voltage pulse is in the range of about 2500V to 4000V, which can penetrate the airway W under a specific parameter combination to treat or affect deep specific cells, such as submucosal cells or smooth muscle cells.
[0060] It will be appreciated that the set voltages 316p, 316n may vary depending on the specific implementation. In bipolar delivery, lower voltages may be used because the electric field is smaller and more directional. In some embodiments, energy is delivered in a bipolar manner and each pulse is in the range of about 100V to 1900V, particularly 100V to 999V, and more particularly about 500V to 800V, such as 500V, 550V, 600V, 650V, 700V, 750V, 800V. In other embodiments, energy is delivered in a bipolar manner and each pulse is between about 50 and 5000 volts, including 250 to 1500 volts.
[0061] The voltage selected for bipolar therapy depends on the separation distance of the electrodes, while the monopolar electrode configuration using remote dispersive pad electrodes can be less concerned with the precise placement of the catheter electrode and the dispersive electrode on the body. In the monopolar electrode embodiment, due to the dispersive behavior of the delivered energy through the body to the dispersive electrode (effective separation distance is about 10 cm to 100 cm), a larger voltage is generally used. In contrast, in the bipolar electrode configuration, the relatively close active area of the electrodes, about 0.5 mm to 10 cm (including 1 mm to 1 cm), has a greater impact on the electrical energy density and effective dose delivered to the tissue from the separation distance. For example, if the target voltage to distance ratio is 3000 V / cm to induce the desired clinical effect at the appropriate tissue depth (1-3 mm), if the separation distance changes from 1 mm to 1.2 mm, this will result in a necessary increase in the treatment voltage from 300 V to about 360 V, a change of 20%.
[0062] The number of biphasic cycles per second is the frequency. In some embodiments, biphasic pulses are used to reduce undesirable muscle stimulation, particularly myocardial stimulation. In other embodiments, the pulse waveform is monophasic, has no clear natural frequency, but can be considered the fundamental frequency by doubling the monophasic pulse length. In some embodiments, the frequency of the signal is in the range of 10kHz-10MHz, more particularly 100kHz-1MHz, or more particularly 100kHz–1000kHz. In some embodiments, the signal has a frequency in the range of about 100-600kHz, which generally penetrates the airway to treat or affect specific cells in a deeper position, such as submucosal cells or smooth muscle cells. In some embodiments, the signal has a frequency in the range of about 600kHz-1000kHz or 600kHz-1MHz, which generally penetrates the airway wall W to treat or affect specific cells that are shallower, such as epithelial cells. It can be understood that at certain voltages, frequencies of 300kHz or less may cause undesirable muscle stimulation. Thus, in some embodiments, the frequency range of the signal is 400-800kHz or 500-800kHz, such as 500kHz, 550kHz, 600kHz, 650kHz, 700kHz, 750kHz, 800kHz. In particular, in some embodiments, the frequency of the signal is 600kHz. In addition, cardiac synchronization is often utilized during sensitive rhythms to reduce or avoid undesirable myocardial stimulation. It will be appreciated that even higher frequencies may be used with components that minimize signal artifacts.
[0063] Figure 4 Shown by Figure 2 The controller 203 (eg, Figure 1A and Figure 1B The processor 154 in the embodiment of the present invention generates signals which are used to control switches Sa1, Sa2, Sb1 and Sb2 to generate Figure 3 The biphasic therapy signal 300 is shown. The switches described above collectively provide a switch network. Figure 4 In the embodiment, the phase 1 uplink signal 402 is used to control the switch Sa1, the phase 1 downlink signal is used to control the switch Sa2, the phase 2 uplink signal 406 is used to control the switch Sb1, and the phase 2 downlink signal 408 is used to control the switch Sb2. Figure 2 , Figure 3 and Figure 4 In the time period between time t1 and time t2, the phase 1 uplink signal 402 turns on (ie, closes) the switch Sa1, and the phase 1 downlink signal 408 turns on (ie, closes) the switch Sb2, while the phase 2 downlink signal 404 keeps the switch Sa2 off (ie, open), and the phase 2 uplink signal 406 keeps the switch Sb1 off (ie, open), thereby generating the following: Figure 3 A first positive pulse peak 308 is shown.
[0064] During the time period between time t2 and time t3, the phase 1 uplink signal 402 disconnects (i.e., opens) the switch Sa1, and the phase 1 downlink signal 408 disconnects (i.e., opens) the switch Sb2, and the phase 2 downlink signal 404 connects (i.e., closes) the switch Sa2, and the phase 2 uplink signal 406 connects (i.e., opens) the switch Sb1, which results in Figure 3 The first negative pulse peak 310 is shown. During the time period between time t3 and time t4, the phase 1 up signal 402 keeps the switch Sa1 off (i.e., open), the phase 1 down signal 408 keeps the switch Sb2 off (i.e., open), and the phase 2 down signal 404 makes the switch Sa2 off (i.e., open), and the phase 2 up signal 406 makes the switch Sb1 off (i.e., open), which results in Figure 3 The dead time 312 after the first negative pulse peak 310 is shown in FIG. In the time period between time t4 and time t5, the phase 1 up signal 402 turns on (i.e., closes) the switch Sa1, and the phase 1 down signal 408 turns on (i.e., closes) the switch Sb2, while the phase 2 down signal 404 keeps the switch Sa2 off (i.e., open), and the phase 2 up signal 406 keeps the switch Sb1 off (i.e., open), which results in the following: Figure 3 The second positive pulse peak 308' is shown. In the time period between time t5 and time t6, the phase 1 up signal 402 disconnects the switch Sa1 (i.e., opens), and the phase 1 down signal 408 disconnects the switch Sb2 (i.e., opens), while the phase 2 down signal 404 connects the switch Sa2 (i.e., closes), and the phase 2 up signal 406 connects the switch Sb1 (i.e., disconnects), which results in the following: Figure 3 The second negative pulse peak 310' is shown. During the time period between time t6 and time t7, the phase 1 up signal 402 keeps the switch Sa1 off (i.e., open), and the phase 1 down signal 408 keeps the switch Sb2 off (i.e., open), the phase 2 down signal 404 makes the switch Sa2 off (i.e., open), and the phase 2 up signal 406 makes the switch Sb1 off (i.e., open), which results in Figure 3 Another dead time after the second negative pulse peak 310' is shown in FIG. Additional positive pulse peaks and negative pulse peaks (eg, 308" and 310") and additional dead times may be generated in a similar manner as needed.
[0065] review Figure 1A and Figure 1B, the generator 104 can measure tissue parameters, such as tissue impedance, in order to select appropriate treatment parameters, such as current level and / or voltage level. In addition, according to certain embodiments of the present technology, the generator 104 can use target current control and / or target voltage control to control the level of tissue treatment.
[0066] With target current control (which may also be referred to as current set point control), the voltage is adjusted so as to treat the tissue with the target current. More specifically, with target current control, the tissue impedance is measured and the voltage is selected to achieve the target current. For example, if the target current is 30 amperes (A) and the measured tissue impedance is 100 ohms (Ω), the voltage may be adjusted to 3000 volts (V) because V=I*R=30A*100Ω=3000V. For another example, if the target current is 30 amperes (A) and the measured tissue impedance is 80 ohms (Ω), the voltage may be adjusted to 2400 volts (V) because V=I*R=30A*80Ω=2400V. For another example, if the target current is 30 amperes (A) and the measured tissue impedance is 120 ohms (Ω), the voltage may be adjusted to 3600 volts (V) because V=I*R=30A*120Ω=3600V. The HV voltage sensing circuit 210 can be used to determine when the voltage stored on the HV capacitor 206 is at a desired level. Alternatively or additionally, the HV voltage sensing circuit 212 can be used to determine whether the target voltage is delivered to the patient tissue and can be used as feedback to increase or decrease the voltage level to which the HV capacitor 206 should be charged. The HV current sensing circuit 214 can be used to measure the current delivered to the patient tissue through the active electrode 108, and the measured value can be used as feedback to increase or decrease the voltage level to which the HV capacitor 206 should be charged. The advantage of using target current control (also referred to as current set point control) is that the target current control enables the tissue treatment system to compensate for electrode array and tissue impedance changes when delivering PEF treatment. This allows for a more consistent treatment effect, thereby producing a more predictable result. This allows for improved efficacy, especially for patients with high tissue impedance, and can also improve safety by reducing the possibility of overtreatment, injury, and arc discharge in patients with low tissue impedance.
[0067] With target voltage control (which may also be referred to as voltage set point control), the current is adjusted so as to treat the tissue with a target voltage. More specifically, with target voltage control, tissue impedance is measured and the current is selected to achieve the target voltage. For example, if the target voltage is 3000V and the measured tissue impedance is 100Ω, the current can be adjusted to 30A because I=V / R=3000V / 100Ω=30A. For another example, if the target voltage is 3000V and the measured tissue impedance is 80 ohms (Ω), the current can be adjusted to 37.5A because I=V / R=3000V / 80Ω=37.5A. For another example, if the target voltage is 3000V and the measured tissue impedance is 120Ω, the current can be adjusted to 25A because I=V / R=3000V / 120Ω=25A.
[0068] It can be understood from the above discussion that whether the generator 104 performs target current control or target voltage control, the tissue impedance should be measured so that the tissue treatment voltage level or current level can be appropriately adjusted as needed to provide the target current or target voltage. According to some embodiments, the active electrode 108 of the device 102 is advanced to the desired position, a relatively low voltage pulse (e.g., 100V) is delivered, and a current sensing circuit (e.g., Figure 2 214) measures the current and calculates the impedance using the equation R=V / I to measure tissue impedance (for a specific location in a specific body cavity, such as the pulmonary vein). For example, if the measured current is 0.8A, the tissue impedance can be calculated as R=100V / 0.8A=125Ω. For another example, if the measured current is 1.0A, the tissue impedance can be calculated as R=100V / 1.0A=100Ω. The reason for using a relatively low voltage pulse (e.g., 100V) to determine tissue impedance is that the voltage pulse should be lower than the level at which the therapeutic effect occurs. According to certain embodiments of the present technology, the voltage of the low-voltage pulse used to determine tissue impedance is in the range of 1V to 100V, but is not limited to this. The low-voltage (LV) pulse or more generally LV signal generated and used to determine tissue impedance may be referred to herein as an LV impedance measurement signal. In contrast, the high-voltage (HV) pulse or more generally HV signal generated and used for treatment may be referred to herein as an HV tissue treatment signal, or more concisely as an HV treatment signal.
[0069] The LV tissue impedance measurement signal discussed herein includes one or more voltage pulses, each having a peak-to-peak voltage of no more than 100 V, more specifically, a peak-to-peak voltage in the range of 1 V to 100 V. The HV tissue treatment signal discussed herein includes one or more voltage pulses, each having a peak-to-peak voltage of at least 500 V, more specifically, a peak-to-peak voltage in the range of 500 V to 10,000 V. In a specific embodiment, the peak-to-peak voltage of each pulse of the HV tissue treatment signal is at least five times the peak-to-peak voltage of each pulse of the LV tissue impedance measurement signal, for example, if the LV voltage pulse is 50 V, the HV voltage pulse is at least 500 V.
[0070] review Figure 2 , if the output signal generator 158 is used to generate an HV therapy signal (e.g., in the range of 2500V to 3500V), and to generate an LV impedance measurement signal (e.g., in the range of 10V to 100V) for determining tissue impedance, the voltage stored on the HV capacitor 206 needs to be significantly reduced each time the output signal generator 158 is switched from generating the HV therapy signal to generating the LV impedance measurement signal. In addition, the voltage stored on the HV capacitor 206 needs to be significantly increased each time the output signal generator 158 is switched from generating the LV impedance measurement signal to generating the HV therapy signal. This increase and decrease in the voltage stored on the HV capacitor 206 can be time consuming, which can increase the overall time required for a physician to perform a treatment procedure.
[0071] According to certain embodiments of the present technology, rather than relying on the same circuit to generate the HV therapy signal and the LV impedance measurement signal, a separate circuit is used to generate the LV impedance measurement signal, and a separate circuit is used to generate the HV therapy signal. In such embodiments, the same controller (e.g., an FPGA or processor) can be used to control the generation of the HV therapy signal and the LV impedance measurement signal. Figure 5A A high-level block diagram of such an embodiment is shown in .
[0072] refer to Figure 5A , which shows a HV signal generator 501, a LV signal generator 502 and a controller 503, wherein the controller 503 is used to control the HV signal generator 501 and the LV signal generator 502 to generate a HV treatment signal and a LV impedance measurement signal respectively. Figure 5A , the HV signal generator 501 is shown to include the HV power supply 202, the HV capacitor 206 and the waveform shaping circuit 208, which have been referred to above. Figure 2 In other embodiments, the HV signal generator 501 may include alternative and / or additional circuits.
[0073] Still refer to Figure 5A The HV voltage sensing circuit 212 is used to sense the voltage between the active electrode 108 and the return electrode 140 when the HV signal generator 501 is being used and / or is about to be used to generate the HV therapy signal. The HV current sensing circuit 214 is used to sense the current transmitted through the active electrode 108 when the HV signal generator 501 is being used and / or is about to be used to generate the HV therapy signal. Figure 5A Also shown is an LV voltage sensing circuit 512 for sensing the voltage between the active electrode 108 and the return electrode 140 when the LV signal generator 503 is being used and / or is about to be used to generate an HV therapy signal. An LV current sensing circuit 514 is used to sense the current transmitted through the active electrode 108 when the LV signal generator 503 is being used and / or is about to be used to generate an LV impedance measurement signal.
[0074] An advantage of using HV voltage sensing circuit 212 when an HV therapy signal is being generated and using LV voltage sensing circuit 512 when an LV impedance measurement signal is being generated is that the resolution of the measurement produced by sensing circuit 212 and the resolution of the measurement produced by sensing circuit 512 can be specifically tailored and optimized for the expected HV measurement range and the expected LV measurement range, respectively. In contrast, if the same voltage sensing circuit is used to sense the voltage between active electrode 108 and return electrode 140 when HV signal generator 501 is being used, and to sense the voltage between active electrode 108 and return electrode 140 when LV signal generator 502 is being used, the resolution of the HV measurement and / or LV measurement will be affected (i.e., less than ideal).
[0075] An advantage of using HV current sensing circuit 214 when the HV therapy signal is being generated and using LV current sensing circuit 514 when the LV impedance measurement signal is being generated is that the resolution of the measurement produced by sensing circuit 214 and the resolution of the measurement produced by sensing circuit 514 can be specifically tailored and optimized for the range of expected HV current measurements and the range of expected LV current measurements, respectively. In contrast, if the same current sensing circuit is used to sense the current provided to active electrode 108 when HV signal generator 501 is being used and to sense the current provided to active electrode 108 when LV signal generator 502 is being used, the resolution of the HV current measurement and / or the LV current measurement will be affected (i.e., less than ideal).
[0076] Figure 5B 5 shows example details of how the LV signal generator 502 can be implemented in a similar manner as the HV signal generator 501. Figure 5B, in this example, the LV signal generator 502 is shown to include an LV power supply 504, an LV capacitor 506, and a waveform shaping circuit 508. The LV power supply 504 is configured to selectively provide a low voltage DC signal for charging the LV capacitor 206 to a desired voltage level. In some embodiments, a voltage sensing circuit 510 can be used to determine when the LV capacitor 506 is charged to a desired voltage level, but this is not necessarily the case. The LV power supply 504 may include, for example, an AC / DC converter that receives an AC signal and outputs a DC signal. The LV power supply 504 may also include a step-up or step-down regulator that receives the output of the AC / DC converter and converts the output of the AC / DC converter to a desired voltage level and maintains the voltage level at a desired level. As will be appreciated by those of ordinary skill in the art, the LV power supply 504 may include additional and / or alternative circuits. The switch Sp2 is used to selectively connect the LV power supply 504 to the LV capacitor 506. In addition to (or in addition to) using switch Sp2 to control whether LV power supply 504 will charge LV capacitor 506, the output of LV power supply 504 can be selectively enabled and disabled by controller 503, thereby selectively controlling whether LV power supply 504 will charge LV capacitor 506 at any given time. Therefore, when controller 503 can selectively enable and disable the output of LV power supply 504, switch Sp2 can be selectively eliminated. Figure 5B In the embodiment of the present invention, LV waveform shaping circuit 508 (similar to waveform shaping circuit 208 described above) can be used to generate a pulse wave or square wave LV impedance measurement signal.
[0077] Still refer to Figure 5B In an alternative embodiment, the LV capacitor 506 may be eliminated entirely if the LV power supply 504 outputs a sufficiently large voltage such that energy does not need to be stored on any capacitor to generate the LV impedance measurement signal. It is also noted that the waveform shaping circuit 508 may be different than that shown (e.g., if the LV impedance measurement signal has a sinusoidal waveform or other shaped waveform). Thus, embodiments of the present technology are not limited to the specific waveform shaping circuits 508 and 208 shown and described herein. For example, when the LV impedance measurement signal is sinusoidal, an oscillator (e.g., a Wien bridge oscillator or a Colpitts type crystal oscillator, but not limited thereto) may be used to implement the LV waveform shaping circuit.
[0078] The leakage resistor 507 is used to selectively release all or part of the energy stored in the LV capacitor 506 by selectively turning on (i.e., closing) the switch S_bleed2. For example, when the controller 503 uses the LV voltage sensing circuit 510 to determine that the voltage stored in the LV capacitor 506 is higher than the desired level, the controller 503 may turn on (i.e., close) the switch S_bleed2 until the voltage stored in the LV capacitor 506 decreases to the desired level, at which time the controller 503 may turn off (i.e., open) the switch S_bleed2. The switch Sp2 and the switch S_bleed2 may be implemented using corresponding insulated gate bipolar transistors (IGBTs), another type of transistor, or a relay, respectively, but are not limited thereto. Depending on the specific implementation, the leakage resistor 507 may be implemented using a group of resistors connected in series and / or in parallel to each other. It is also possible not to include any leakage resistors, but to leak any excess voltage stored in the LV capacitor 506 into the patient's tissue.
[0079] Figure 5C 2 shows example details of how to implement the LV signal generator 502 according to another embodiment, where the HV signal generator 501 and the LV signal generator 502 share the same waveform shaping circuit 208. Figure 5C In the embodiment of , there is a switch Sv, which is controlled by the controller 503 to connect the HV power supply 202 (and / or the HV capacitor 206) to the waveform shaping circuit 208, or to connect the LV power supply 504 (and / or the LV capacitor 506) to the waveform shaping circuit 208. When the switch Sv connects the HV power supply 202 (and / or the HV capacitor 206) to the waveform shaping circuit 208, the waveform shaping circuit 208 is part of the HV signal generator 501. When the switch Sv connects the LV power supply 504 (and / or the LV capacitor 506) to the waveform shaping circuit 208, the waveform shaping circuit 208 is part of the LV signal generator 502. Still referring to Figure 5C In one embodiment, if the LV power supply 504 outputs a sufficiently large voltage that no energy needs to be stored on any capacitor to generate the LV impedance measurement signal, the LV capacitor 506 can be eliminated entirely. It is also noted that the waveform shaping circuit 208 shared by the two generators 501, 502 can be different than shown and still be within the scope of the embodiments described herein.
[0080] Figure 5D 5 shows example details of how to implement LV signal generator 502 according to another embodiment. Figure 5DIn the illustrated embodiment, when the Sp switch is closed and / or the HV power supply 202 is enabled, and the Sv1 switch is closed and the Sv2 switch is open, the HV power supply will charge one or more HV capacitors 206, and will charge one or more LV capacitors 506. Because the capacitance of the LV capacitor 506 is significantly smaller than the capacitance of the HV capacitor 206 (e.g., no more than one-fifth of the capacitance of the HV capacitor 206), the magnitude of the voltage stored on the LV capacitor 506 will be significantly smaller than the magnitude of the voltage stored jointly on the HV capacitor 206 and the LV capacitor 506 (e.g., no more than one-fifth of the voltage stored jointly in the HV capacitor 206 and the LV capacitor 506). Figure 5D In an embodiment of the present invention, when switch Sv1 is closed and switch Sv2 is open, the charge stored jointly on the HV capacitor 206 and the LV capacitor 506 is provided to the waveform shaping circuit 208 and used to generate the HV therapy signal. When switch Sv is open and switch Sv2 is closed, only the charge stored on the LV capacitor 506 is provided to the waveform shaping circuit 208 and used to generate the LV impedance measurement signal. In this way, the HV power supply 202 is shared by the HV signal generator 501 and the LV signal generator 502. Other variations are also possible and are within the scope of the embodiments described herein. For example, a single-pole double-throw switch can be used instead of the two single-pole single-throw switches Sv1 and Sv2, so that when the single-pole double-throw switch is in a first position, the voltage stored jointly on the HV capacitor 206 and the LV capacitor 506 is provided to the waveform shaping circuit 208 and used to generate the HV therapy signal, and when the single-pole double-throw switch is in a second position, only the voltage stored on the LV capacitor is provided to the waveform shaping circuit 208 and used to generate the LV impedance measurement signal.
[0081] More generally, in Figure 5D In an embodiment of the present invention, the controller 503 can control various switches to connect a first subset of capacitors 206, 506 to the waveform shaping circuit 208 during a first time period when an LV tissue impedance measurement signal is transmitted to the patient tissue through the electrodes 108, 140, and to connect a second subset of capacitors 206, 506 to the waveform shaping circuit 208 during a second time period when an HV tissue treatment signal is transmitted to the patient tissue through the electrodes 108, 140. In such an embodiment, the voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal. In addition, in such an embodiment, the first subset of capacitors includes at least one of the plurality of capacitors 206, 506, and the second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset. Figure 5DIn the embodiment, the leakage resistor 207 can be used to selectively release all or part of the energy stored in the capacitors 206 and 506 by selectively turning on (ie, closing) the switch S_bleed. It is also possible not to include any leakage resistors, but to leak any excess voltage stored in the capacitors 206 and 506 into the patient's tissue.
[0082] exist Figure 5A , Figure 5B , Figure 5C as well as Figure 5D In the embodiment, when the HV signal generator 501 is being used and / or is about to be used to generate the HV therapy signal, the HV voltage sensing circuit 212 is used to sense the voltage between the active electrode 108 and the return electrode 140, and when the LV signal generator 503 is being used and / or is about to be used to generate the HV therapy signal, the LV voltage sensing circuit 512 is used to sense the voltage between the active electrode 108 and the return electrode 140. The advantage of using the HV voltage sensing circuit 212 when the HV therapy signal is being generated and the LV voltage sensing circuit 512 when the LV impedance measurement signal is generated is that the resolution of the measurement generated by the sensing circuit 212 and the resolution of the measurement generated by the sensing circuit 512 can be specifically customized and optimized for the range of the expected HV measurement and the range of the expected LV measurement, respectively. In an alternative embodiment, the same voltage sensing circuit can be used regardless of whether the HV therapy signal or the LV impedance measurement signal is generated. However, in such an alternative embodiment, the resolution of the HV voltage measurement and / or the LV voltage measurement will be affected (i.e., less than ideal).
[0083] exist Figure 5A , Figure 5B , Figure 5C as well as Figure 5D , the HV current sensing circuit 214 is used when generating the HV therapy signal, and the LV current sensing circuit 514 is used when generating the LV impedance measurement signal. The advantage of using the HV current sensing circuit 214 when generating the HV therapy signal and the LV current sensing circuit 514 when generating the LV impedance measurement signal is that the resolution of the measurement produced by the sensing circuit 214 and the resolution of the measurement produced by the sensing circuit 514 can be specifically customized and optimized for the range of expected HV current measurements and the range of expected LV current measurements, respectively. In an alternative embodiment, the same current sensing circuit is used to sense the current provided to the active electrode 108 when using the HV signal generator 501, and to sense the current provided to the active electrode 108 when using the LV signal generator 502. However, in such an alternative embodiment, the resolution of the HV current measurement and / or the LV current measurement will be affected (i.e., less than ideal).
[0084] exist Figure 5A , Figure 5B , Figure 5C as well as Figure 5D , as will be appreciated by one of ordinary skill in the art, the output signal generator circuit 158 may include additional circuitry not shown. For example, a step-up transformer, a filter, and / or a DC blocking capacitor may be optionally connected between the output nodes (labeled as OUT1 and OUT2) of the waveform shaping circuit 208 and the active electrode 108 and the return electrode 140. Such a step-up transformer may be used to step up the voltage signal generated between the output nodes (OUT1 and OUT2) of the waveform shaping circuit 208 to a desired level, as well as to isolate the HV power supply 202 and the waveform shaping circuit 208 from the electrodes 108 and 140. Such a filter may be, for example, an RC snubber circuit including a resistor and a capacitor connected in series between the electrodes 108 and 140, which may be used to filter out high frequency transients or ringing that may be caused by the leakage inductance of the transformer. Such a DC blocking capacitor may be used to prevent low frequency or DC current from inadvertently flowing through the patient's tissue.
[0085] In some embodiments, when the LV tissue impedance measurement signal (generated using the LV signal generator 502) is transmitted to the patient tissue, the LV current sensing circuit 514 measures the current transmitted to the patient tissue via the active electrode 108, and when the HV tissue therapy measurement signal (generated using the HV signal generator 501) is transmitted to the patient tissue, the HV current sensing circuit 214 measures the current transmitted to the patient tissue via the active electrode 108. In such embodiments, the controller 503 can generate an estimate of the patient tissue impedance based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the LV current sensing circuit 514. In addition, the controller 503 can set the voltage of the HV tissue therapy signal (generated using the HV signal generator 501) based on the estimate of the patient tissue impedance, and the controller 503 can adjust the voltage of the HV tissue therapy signal (generated using the HV signal generator 501) based on the current measured by the HV current sensing circuit 214.
[0086] The terms high voltage (HV) and low voltage (LV) as used herein are relative terms to each other, where a voltage considered to be HV is at least five times a voltage considered to be LV. In a particular embodiment, the voltage of the LV signal does not exceed 100V, and the voltage of the HV signal is at least five times that of the LV signal. In certain embodiments, the amplitude of the HV signal is at least 1000V. More generally, the LV signals described herein are used to measure the impedance of patient tissue, rather than for treating (e.g., ablating) tissue, and therefore, the LV signals are generally referred to herein as LV tissue impedance measurement signals. In contrast, the HV signals described herein are used to treat (e.g., ablate) tissue, and therefore, the HV signals are generally referred to herein as HV tissue treatment signals, or more concisely as HV treatment signals.
[0087] In the above reference Figure 5A-5D In each of the embodiments described, Figure 1A and Figure 1B The output signal generator 158 of the signal generator 104 introduced in the embodiment is shown to include both the HV signal generator 501 and the LV signal generator 502, and includes a controller 503. In such an embodiment, the LV signal generator 502 is used to generate an LV tissue impedance measurement signal, and the HV signal generator 501 is used to generate an HV tissue treatment signal, the voltage of which is at least five times the voltage of the LV tissue impedance measurement signal. The controller 503 controls when the HV tissue treatment signal (generated using the HV signal generator 501) is transmitted to the patient tissue through the active electrode 108 and the return electrode 140 and when the LV tissue impedance measurement signal (generated using the LV signal generator 502) is transmitted to the patient tissue through the active electrode 108 and the return electrode 140. As shown from Figures 5A-5D As can be understood from the above discussion, the controller 503 can control Figure 5A-5D The various switches shown in FIG. 1 are used to control the generation and transmission of these signals, and / or to control when various components (eg, power supplies) are enabled or disabled.
[0088] In some embodiments, when the LV tissue impedance measurement signal generated using the LV signal generator 502 is transmitted to the patient tissue, the LV current sensing circuit 514 measures the current transmitted to the patient tissue through the active electrode 108. In some such embodiments, the controller 503 generates an estimate of the patient tissue impedance based on the voltage of the LV tissue impedance measurement signal (generated using the LV power supply 504) transmitted to the patient tissue and based on the current measured by the LV current sensing circuit 514, and the controller 503 controls the voltage of the HV tissue therapy signal (generated using the HV signal generator 501) based on the estimate of the patient tissue impedance.
[0089] In certain embodiments, the controller 503 controls the voltage of the HV tissue treatment signal (generated using the HV signal generator 501) based on the estimated value of the patient tissue impedance, so that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current. The predetermined target current can be a default target current whose value is stored in a memory or register of the generator 104, or can be specified by a clinician using the user interface 150 of the generator 104.
[0090] In certain embodiments, between each of a plurality of separate instances of using the HV signal generator 501 to generate an HV tissue treatment signal for transmission to patient tissue, the controller 503 causes the LV signal generator 502 to be used to generate an LV tissue impedance measurement signal for transmission to the patient tissue. The controller 503 generates an updated estimate of the patient tissue impedance based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on an updated measurement of the current transmitted to the patient tissue (measured using the LV current sensing circuit 514). Then, if the updated estimate of the patient tissue impedance is different from the immediately previous estimate of the patient tissue impedance, the controller 503 adjusts the voltage of the HV tissue treatment signal generated using the HV signal generator 501. In this manner, the patient tissue is treated with a current approximately equal to a predetermined target current when the HV tissue treatment signal is transmitted to the patient tissue the next time.
[0091] Now we will use Figure 6 The high-level flow chart shown in is used to describe a method according to certain embodiments of the present technology, which is used with an output signal generator (e.g., 158) of a signal generator (e.g., 104), wherein the output signal generator includes an HV signal generator (e.g., 501) and a LV signal generator (e.g., 502). Figure 6 Step 602 involves positioning an active electrode of a therapeutic energy delivery device (e.g., a catheter) so that the active electrode contacts the patient's tissue at the location to be treated. Examples of such active electrodes are described above with reference to Figure 1A The electrode 108 of the device (e.g., catheter) 102 shown and discussed. Step 602 or a separate step may also involve applying a return electrode (e.g., 140) externally to the patient's skin. Alternatively, the return electrode (e.g., 140) may be an implanted electrode, such as an implanted electrode located on a catheter or sheath, but is not limited thereto.
[0092] Still refer to Figure 6 , step 604 involves generating an LV tissue impedance measurement signal and transmitting the LV tissue impedance measurement signal to the patient tissue via the active electrode and the return electrode. The LV tissue impedance measurement signal generated in step 604 can be generated using a signal generator (e.g., 104), or more specifically, can be generated using an output signal generator 158 of the signal generator. Example implementations of the output signal generator 158 are as follows FIG. 5A to FIG. 5D As shown and referenced above FIG. 5A to FIG. 5D A therapeutic energy delivery device (eg, 102) may be used to deliver LV tissue impedance measurement signals to patient tissue at step 602, as described in detail above.
[0093] Step 606 involves measuring the current transmitted to the patient tissue through the active electrode (e.g., 108) when the LV tissue impedance measurement signal is transmitted to the patient tissue. Step 606 can be performed at least in part using a current sensing circuit (e.g., but not limited to, the circuit 514 or 214 described above).
[0094] Step 608 involves generating an estimate of the patient's tissue impedance based on the voltage of the LV tissue impedance measurement signal transmitted to the patient's tissue and based on the measured current. Step 608 may be performed at least in part by a controller (e.g., controller 203 or 503 described above). For example, assuming that the LV tissue impedance measurement signal transmitted in step 604 is a 100V pulse and the current measured in step 606 is 0.8 amperes, then because R = 100V / 0.8A = 125Ω, the estimate generated in step 608 may be 125 ohms. For another example, if the measured current is 1.0A, the tissue impedance may be calculated as R = 100V / 1.0A = 100Ω.
[0095] Step 610 involves generating a HV tissue treatment signal and transmitting the HV tissue treatment signal through the active electrode and the return electrode. As described above, the voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal. As described above, generating the HV treatment signal includes controlling the voltage of the HV tissue treatment signal based on an estimated value of the patient's tissue impedance. For example, assuming that target current control (which may also be referred to as current set point control) is being adopted, step 610 may include adjusting the voltage so as to treat the tissue with the target current. For example, if the target current is 30A and the estimated tissue impedance is 100Ω, then since V=I*R=30A*100Ω=3000V, the voltage can be adjusted to 3000V. For another example, if the target current is 30A and the estimated tissue impedance is 80Ω, then since V=I*R=30A*80Ω=2400V, the voltage can be adjusted to 2400V. For another example, if the target current is 30A and the estimated tissue impedance is 120Ω, the voltage can be adjusted to 3600V because V=I*R=30A*120Ω=3600V. The HV voltage sensing circuit 210 can be used to determine when the voltage stored on the HV capacitor 206 is at a desired level. Alternatively or additionally, the HV voltage sensing circuit 212 can be used to determine whether the target voltage is delivered to the patient tissue and can be used as feedback to increase or decrease the voltage level to which the HV capacitor 206 should be charged. The HV current sensing circuit 214 can be used to measure the current delivered to the patient tissue through the active electrode 108, which measurement can be used as feedback to increase or decrease the voltage level to which the HV capacitor 206 should be charged.
[0096] Still refer to Figure 6, step 612 involves determining whether the patient tissue at the location has been adequately treated. In certain embodiments, because the impedance of successfully treated tissue should be significantly reduced, step 612 may be performed by determining whether the impedance of the patient tissue has been reduced by at least a specified amount. More specifically, steps 604, 606, and 608 may be repeated to generate an updated estimate of the patient tissue impedance, and then a determination may be made whether there has been at least a specified reduction in the patient tissue impedance (e.g., a reduction of at least 50%). If the tissue impedance has not been reduced by at least a specified amount (i.e., if the answer to the determination of step 612 is no), then the patient tissue impedance may be determined to have been reduced by at least a specified amount, as may be determined from Figure 6 As will be appreciated in the foregoing, additional HV tissue treatment signals may be generated and delivered to the same location in another instance of step 610. More specifically, additional instances of steps 604, 606, and 608 may be performed as part of step 612, and then step 610 may be repeated to generate and deliver another HV tissue treatment signal to the same location (using the updated estimate of tissue impedance generated in the most recent instance of step 608). If there is at least a specified decrease in tissue impedance (i.e., if the answer to the determination of step 612 is yes), then the flow proceeds to step 614.
[0097] At step 614, a determination is made as to whether there are any additional patient tissue locations that require treatment. If the answer to the determination at step 614 is no, then the method may end. However, if the answer to the determination at step 614 is yes, then the process proceeds to step 616. At step 616, the active electrode (e.g., 108) is positioned at the new location so that it contacts the additional patient tissue to be treated. The process then returns to step 604, as shown in FIG. Figure 6 Steps 604, 606, 608, 610, and 612 are then performed as the active electrode contacts additional patient tissue to be treated. The process is then repeated until all tissue to be treated has been treated, as can be seen from Figure 6 As understood in .
[0098] As mentioned above Figure 3As explained in the discussion, the HV tissue treatment signal generated and transmitted in each instance of step 610 may include one or more pulse packets, wherein the pulses may be biphasic, or alternatively monophasic. Prior to each transmission of a pulse packet, tissue impedance may be measured in instances of steps 604, 606, and 608, more specifically, estimated, and based on the measured tissue impedance, the voltage may be adjusted as part of an instance of step 610 to treat the tissue with a target current, or the current may be adjusted to treat the tissue with a target voltage, depending on whether target current control or target voltage control is employed. Thereafter, an updated estimate of tissue impedance may be generated to determine whether additional HV tissue treatment signals should be transmitted to a particular patient tissue, or to determine that a particular patient tissue has been adequately treated. In other words, tissue impedance may be estimated and used to adjust voltage or current before an initial HV tissue treatment pulse packet is delivered, and between successive HV treatment pulse packets.
[0099] Depending on the particular implementation, step 612 may be performed after each HV pulse packet generated and delivered in an instance of step 610. Alternatively, step 612 may be performed after a series of HV pulse packets generated and delivered in an instance of step 610. Other variations are possible and are within the scope of the embodiments described herein. Either way, quasi-real-time feedback is provided to determine whether additional treatment is to be provided to the patient tissue location, and if so, such quasi-real-time feedback may be used to adjust the current and / or voltage of the HV tissue treatment pulse delivered in the next instance of step 610. Therefore, reference is made to Figure 6 The summarized embodiments provide for intermittent monitoring of impedance during therapy delivery to determine if additional therapy should be administered at a certain location, or if an active electrode can be moved to a new location.
[0100] Example
[0101] Embodiment 1. A tissue treatment system, comprising: a low voltage (LV) signal generator, which is used to generate an LV tissue impedance measurement signal; a high voltage (HV) signal generator, which is used to generate an HV tissue treatment signal, the voltage of which is at least five times the voltage of the LV tissue impedance measurement signal; and a controller, which is constructed to control when the HV tissue treatment signal generated by the HV signal generator is transmitted to the patient tissue through the active electrode and the return electrode, and when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue through the active electrode and the return electrode.
[0102] Example 2. According to the tissue treatment system described in Example 1, it also includes: a current sensing circuit, which is constructed to measure the current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue; wherein the controller is also constructed to generate an estimated value of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit; and control the voltage of the HV tissue treatment signal generated by the HV signal generator based on the estimated value of the impedance of the patient tissue.
[0103] Example 3. A tissue treatment system according to Example 2, wherein the controller is constructed to control the voltage of the HV tissue treatment signal generated using the HV signal generator based on an estimated value of the impedance of the patient tissue, so that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0104] Embodiment 4. A tissue treatment system according to Embodiment 3, wherein, between each of a plurality of separate instances in which the HV signal generator is used to generate an HV tissue treatment signal for transmission to patient tissue, the controller is constructed to: cause the LV signal generator to generate an LV tissue impedance measurement signal for transmission to the patient tissue; generate an updated estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on an updated measurement value of the current transmitted to the patient tissue measured using a current sensing circuit; and in response to the updated estimate of the impedance of the patient tissue being different from an immediately previous estimate of the impedance of the patient tissue, adjust the voltage of the HV tissue treatment signal generated using the HV signal generator so that when the HV tissue treatment signal is next transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0105] Embodiment 5. A tissue treatment system according to any one of embodiments 1 to 4, wherein: the LV signal generator includes a LV power supply; and the HV signal generator includes a HV power supply different from the LV power supply of the LV signal generator.
[0106] Example 6. A tissue treatment system according to Example 5, wherein: the LV signal generator includes an LV waveform shaping circuit connected between the LV power supply and the active electrode and the return electrode; and the HV signal generator includes an HV waveform shaping circuit that is different from the LV waveform shaping circuit and connected between the HV power supply and the active electrode and the return electrode.
[0107] Embodiment 7. A tissue treatment system according to embodiment 5, wherein: the LV signal generator and the HV signal generator share the same waveform shaping circuit.
[0108] Embodiment 8. According to any one of Embodiments 1 to 7, the tissue treatment system further includes: an LV current sensing circuit, which is constructed to measure the current transmitted to the patient tissue via the active electrode when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue; and an HV current sensing circuit, which is different from the LV current sensing circuit and is constructed to measure the current transmitted to the patient tissue via the active electrode when the HV tissue treatment signal generated by the HV signal generator is transmitted to the patient tissue.
[0109] Example 9. A tissue treatment system according to Example 8, wherein the controller is further constructed to: generate an estimated value of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the LV current sensing circuit; set the voltage of the HV tissue treatment signal generated using the HV signal generator based on the estimated value of the impedance of the patient tissue; and adjust the voltage of the HV tissue treatment signal generated using the HV signal generator based on the current measured by the HV current sensing circuit.
[0110] Embodiment 10. A tissue treatment system, comprising: a pair of electrodes; a plurality of capacitors; a power source configured to charge the plurality of capacitors; a waveform shaping circuit connected between the plurality of capacitors and the pair of electrodes; a controller configured to connect a first subset of the capacitors to the waveform shaping circuit during a first time period when a low voltage (LV) tissue impedance measurement signal is transmitted to patient tissue through the pair of electrodes; and to connect a second subset of the capacitors to the waveform shaping circuit during a second time period when a high voltage (HV) tissue treatment signal is transmitted to patient tissue through the pair of electrodes; wherein a voltage of the HV tissue treatment signal is at least five times a voltage of the LV tissue impedance measurement signal; the first subset of capacitors includes at least one of the plurality of capacitors; and the second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset.
[0111] Embodiment 11. A tissue treatment system according to embodiment 10, wherein: a first subset of power supplies, waveform shaping circuits and capacitors are components of an LV signal generator for generating an LV tissue impedance measurement signal; a second subset of power supplies, waveform shaping circuits and capacitors are components of an HV signal generator for generating an HV tissue treatment signal; and the power supply and waveform shaping circuit are shared by the LV signal generator and the HV signal generator.
[0112] Example 12. A tissue treatment system according to Example 10 or 11, wherein a pair of electrodes includes an active electrode and a return electrode, and the tissue treatment system further includes: a current sensing circuit, which is constructed to measure the current transmitted to the patient tissue via the active electrode when the LV tissue impedance measurement signal is transmitted to the patient tissue; wherein the controller is also constructed to generate an estimated value of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit; and control the voltage of the HV tissue treatment signal based on the estimated value of the impedance of the patient tissue.
[0113] Example 13. A tissue treatment system according to Example 12, wherein the controller is constructed to control the voltage of the HV tissue treatment signal based on an estimated value of the impedance of the patient tissue, so that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0114] Embodiment 14. A tissue treatment system according to Embodiment 13, wherein, between each of multiple separate instances of generating an HV tissue treatment signal and transmitting it to patient tissue, the controller is constructed to: generate an updated estimate of the impedance of the patient tissue; and in response to the updated estimate of the impedance of the patient tissue being different from an immediately previous estimate of the impedance of the patient tissue, adjust the voltage of the generated HV tissue treatment signal so that when the HV tissue treatment signal is next transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
[0115] Embodiment 15. A method comprising the following steps: (a) generating a low voltage (LV) tissue impedance measurement signal and transmitting the LV tissue impedance measurement signal to patient tissue through an active electrode and a return electrode; (b) measuring the current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal is transmitted to the patient tissue; (c) generating an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the measured current; and (d) generating a high voltage (HV) tissue treatment signal and transmitting the HV tissue treatment signal through the active electrode and the return electrode, wherein the voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal, and wherein generating the HV tissue treatment signal comprises controlling the voltage of the HV tissue treatment signal based on the estimate of the impedance of the patient tissue.
[0116] Example 16. A method according to Example 15, wherein steps (a), (b), (c) and (d) are performed in sequence, and after being performed in this sequence, steps (a), (b), (c) and (d) are repeated in this sequence, so that an updated estimate of the impedance of the patient tissue is generated when step (c) is repeated, and so that when step (d) is repeated, the voltage of the HV tissue treatment signal is controlled based on the updated estimate of the impedance of the patient tissue.
[0117] Example 17. A method according to Example 15, wherein steps (a), (b), (c) and (d) are performed in the order described, and after being performed in the order described, steps (a), (b) and (c) are repeated in the order described to generate an updated estimate of the impedance of the patient tissue, and the method further includes: determining whether the treatment of the patient tissue is sufficient or whether the patient tissue should be additionally treated in an additional instance of step (d) based on the updated estimate of the impedance of the patient tissue.
[0118] Embodiment 18. A method according to Embodiment 17, wherein, when additional treatment is to be performed on the patient tissue in an additional instance of step (d), generating the HV treatment signal in the additional instance of step (d) includes controlling the voltage of the HV tissue treatment signal based on an updated estimate of the impedance of the patient tissue.
[0119] Example 19. A method according to any one of Examples 15 to 18, wherein: generating the LV tissue impedance measurement signal in step (a) is performed using an LV signal generator; and generating the HV tissue treatment signal in step (c) is performed using an HV signal generator different from the LV signal generator.
[0120] Example 20. The method according to any one of Examples 15 to 19 further includes: charging a plurality of capacitors using a power supply; using a waveform shaping circuit connected between the plurality of capacitors and the active electrode and the return electrode to shape the LV tissue impedance measurement signal and the HV tissue treatment signal; wherein, generating and transmitting the LV tissue impedance measurement signal in step (a) includes connecting a first subset of capacitors to the waveform shaping circuit during a first time period; generating and transmitting the HV tissue treatment signal in step (c) includes connecting a second subset of capacitors to the waveform shaping circuit during a second time period; the first subset of capacitors includes at least one of the plurality of capacitors; and the second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset.
[0121] It should be understood that the application of the subject matter described herein is not limited to the construction details and component arrangements set forth in the description described herein or shown in the drawings herein. The subject matter described herein can include other embodiments and can be implemented or executed in various ways. In addition, it should be understood that the words and terms used herein are for descriptive purposes and should not be considered as limiting. "Including," "including," or "having" and their variations used herein are intended to cover the items listed thereafter and their equivalents as well as additional items. In addition, it should be noted that, unless otherwise stated, the term "based on" used herein should be interpreted as at least partially based on the meaning, meaning that there may be one or more other factors on which decisions are made, etc. For example, if a decision is based on a comparison result, the decision may be based on one or more other factors in addition to the comparison result.
[0122] Embodiments of the present technology are described with the aid of functional component blocks that illustrate the execution of specific functions and their relationships. The boundaries of these functional component blocks are generally defined herein to facilitate description. As long as the specific functions and their relationships are properly executed, alternative boundaries may be defined. Therefore, any such alternative boundaries are within the scope and spirit of the claimed invention. For example, the components may be combined or separated. FIG. 5A to FIG. 5D Some of the steps shown in , and change the order of each step. For another example, you can change Figure 1A to Figure 2 Boundaries of some of the boxes shown in C.
[0123] It should be understood that the above description is intended to be illustrative, not restrictive. For example, the above embodiments (and / or aspects thereof) may be used in combination with each other. In addition, many modifications may be made to adapt specific situations or materials to the teachings of the present technology embodiments without departing from the scope thereof. Many other embodiments will be clear to those skilled in the art after reading the above description. Therefore, the scope of the present technology embodiments should be determined with reference to the attached claims and the full scope of equivalents enjoyed by these claims. In the attached claims, the terms "including" and "wherein" are used as the plain English equivalents of the corresponding terms "including" and "wherein". In addition, in the following claims, the terms "first", "second" and "third" etc. are used only as labels and are not intended to impose numerical requirements on their objects. In addition, the limitations of the attached claims are not written in a mechanism plus function format, nor are they intended to be interpreted based on 35 U.SC § 112 (f), unless and until such claim limitations explicitly use the phrase "mechanism" with a functional statement without further structure.
Claims
1. A tissue treatment system comprising: a low voltage (LV) signal generator for generating a LV tissue impedance measurement signal; a high voltage (HV) signal generator for generating an HV tissue treatment signal having a voltage at least five times greater than a voltage of the LV tissue impedance measurement signal; as well as A controller configured to control when the HV tissue treatment signal generated by the HV signal generator is transmitted to the patient tissue through the active electrode and the return electrode, and when the LV tissue impedance measurement signal generated by the LV signal generator is transmitted to the patient tissue through the active electrode and the return electrode.
2. The tissue treatment system according to claim 1, further comprising: a current sensing circuit configured to measure a current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal generated using the LV signal generator is transmitted to the patient tissue; Wherein, the controller is further configured as follows: generating an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit; and Based on the estimate of the impedance of the patient tissue, a voltage of the HV tissue therapy signal generated using the HV signal generator is controlled.
3. The tissue treatment system according to claim 2, wherein: The controller is configured to control a voltage of the HV tissue treatment signal generated using the HV signal generator based on an estimated value of the impedance of the patient tissue, so that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
4. The tissue treatment system according to claim 3, wherein: Between each of a plurality of separate instances in which the HV signal generator is used to generate the HV tissue therapy signal that is transmitted to the patient tissue, the controller is configured to: causing the LV signal generator to generate the LV tissue impedance measurement signal to be transmitted to tissue of the patient; generating an updated estimate of impedance of the patient tissue based on a voltage of the LV tissue impedance measurement signal delivered to the patient tissue and based on an updated measurement of current delivered to the patient tissue measured using the current sensing circuit; as well as In response to the updated estimate of the impedance of the patient tissue being different from an immediately previous estimate of the impedance of the patient tissue, the voltage of the HV tissue treatment signal generated using the HV signal generator is adjusted so that when the HV tissue treatment signal is next transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to the predetermined target current.
5. A tissue treatment system according to any one of claims 1 to 4, wherein: The LV signal generator includes a LV power supply; and The HV signal generator includes an HV power supply different from an LV power supply of the LV signal generator.
6. The tissue treatment system of claim 5, wherein: The LV signal generator includes an LV waveform shaping circuit coupled between the LV power supply and the active electrode and the return electrode; as well as The HV signal generator includes an HV waveform shaping circuit that is distinct from the LV waveform shaping circuit and is coupled between the HV power source and the active electrode and the return electrode.
7. The tissue treatment system of claim 5, wherein: The LV signal generator and the HV signal generator share the same waveform shaping circuit.
8. The tissue treatment system according to any one of claims 1 to 7, further comprising: an LV current sensing circuit configured to measure a current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal generated using the LV signal generator is transmitted to the patient tissue; as well as A HV current sensing circuit is different from the LV current sensing circuit and is configured to measure current transmitted to the patient tissue through the active electrode when the HV tissue therapy signal generated by the HV signal generator is transmitted to the patient tissue.
9. The tissue treatment system according to claim 8, wherein: The controller is also configured as follows: generating an estimate of impedance of the patient tissue based on a voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the LV current sensing circuit; setting a voltage of the HV tissue therapy signal generated using the HV signal generator based on an estimate of the impedance of the patient tissue; as well as A voltage of the HV tissue therapy signal generated using the HV signal generator is adjusted based on the current measured by the HV current sensing circuit.
10. A tissue treatment system comprising: a pair of electrodes; Multiple capacitors; a power source configured to charge the plurality of capacitors; a waveform shaping circuit connected between the plurality of the capacitors and the pair of electrodes; A controller, wherein the controller is configured to: coupling a first subset of the capacitors to the waveform shaping circuit during a first time period of transmitting a low voltage (LV) tissue impedance measurement signal to patient tissue via the pair of electrodes; and coupling a second subset of the capacitors to the waveform shaping circuit during a second time period of delivering a high voltage (HV) tissue therapy signal to the patient tissue via the pair of electrodes; in, The voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal; The first subset of capacitors includes at least one of the plurality of capacitors; and The second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset.
11. The tissue treatment system of claim 10, wherein: The power supply, the waveform shaping circuit, and the first subset of capacitors are components of an LV signal generator for generating the LV tissue impedance measurement signal; The power supply, the waveform shaping circuit, and the second subset of capacitors are components of an HV signal generator for generating the HV tissue treatment signal; and The power supply and the waveform shaping circuit are shared by the LV signal generator and the HV signal generator.
12. The tissue treatment system according to claim 10 or 11, wherein: The pair of electrodes includes an active electrode and a return electrode, and the tissue treatment system further includes: a current sensing circuit configured to measure a current transmitted to the patient tissue through the active electrode when the LV tissue impedance measurement signal is transmitted to the patient tissue; Wherein, the controller is further configured as follows: generating an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the current measured by the current sensing circuit; and Based on the estimate of the impedance of the patient tissue, the voltage of the HV tissue therapy signal is controlled.
13. The tissue treatment system of claim 12, wherein: The controller is configured to control a voltage of the HV tissue treatment signal based on an estimate of the impedance of the patient tissue such that when the HV tissue treatment signal is transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to a predetermined target current.
14. The tissue treatment system of claim 13, wherein: Between each of a plurality of separate instances in which the HV tissue treatment signal is generated and transmitted to the patient tissue, the controller is configured to: generating an updated estimate of impedance of tissue of the patient; and In response to an updated estimate of the impedance of the patient tissue being different from an immediately previous estimate of the impedance of the patient tissue, the voltage of the generated HV tissue treatment signal is adjusted so that when the HV tissue treatment signal is next transmitted to the patient tissue, the patient tissue is treated with a current approximately equal to the predetermined target current.
15. A method comprising the steps of: (a) generating a low voltage (LV) tissue impedance measurement signal and transmitting the LV tissue impedance measurement signal to a patient's tissue via an active electrode and a return electrode; (b) measuring a current delivered to the patient tissue through the active electrode while delivering the LV tissue impedance measurement signal to the patient tissue; (c) generating an estimate of the impedance of the patient tissue based on the voltage of the LV tissue impedance measurement signal transmitted to the patient tissue and based on the measured current; as well as (d) generating a high voltage (HV) tissue treatment signal and transmitting the HV tissue treatment signal through the active electrode and the return electrode, wherein the voltage of the HV tissue treatment signal is at least five times the voltage of the LV tissue impedance measurement signal, and wherein generating the HV tissue treatment signal includes controlling the voltage of the HV tissue treatment signal based on an estimate of the impedance of the patient tissue.
16. The method according to claim 15, wherein: Steps (a), (b), (c) and (d) are performed in sequence, and after being performed in the sequence, steps (a), (b), (c) and (d) are repeated in the sequence, so that an updated estimate of the impedance of the patient tissue is generated when step (c) is repeated, and so that when step (d) is repeated, the voltage of the HV tissue treatment signal is controlled based on the updated estimate of the impedance of the patient tissue.
17. The method according to claim 15, wherein: Steps (a), (b), (c) and (d) are performed in the order described, and after being performed in the order described, steps (a), (b) and (c) are repeated in the order described to produce an updated estimate of the impedance of the patient's tissue, and the method further comprises: Based on the updated estimate of the impedance of the patient tissue, it is determined whether the treatment of the patient tissue is sufficient or whether additional treatment should be performed on the patient tissue in an additional instance of step (d).
18. The method according to claim 17, wherein: When additional treatment is to be provided to the patient tissue in an additional instance of step (d), generating the HV therapy signal in an additional instance of step (d) includes controlling a voltage of the HV tissue therapy signal based on an updated estimate of the impedance of the patient tissue.
19. The method according to any one of claims 15 to 18, wherein: Generating the LV tissue impedance measurement signal in step (a) is performed using an LV signal generator; and Generating the HV tissue treatment signal in step (c) is performed using a HV signal generator that is different from the LV signal generator.
20. The method according to any one of claims 15 to 19, further comprising: Using a power source to charge a plurality of capacitors; shaping the LV tissue impedance measurement signal and the HV tissue therapy signal using a waveform shaping circuit coupled between a plurality of the capacitors and the active electrode and the return electrode; in, Generating and transmitting the LV tissue impedance measurement signal in step (a) includes coupling a first subset of the capacitors to the waveform shaping circuit for a first time period; Generating and transmitting the HV tissue treatment signal in step (c) includes coupling a second subset of the capacitors to the waveform shaping circuit for a second time period; The first subset of capacitors includes at least one of the plurality of capacitors; and The second subset of capacitors includes at least one of the plurality of capacitors and is different from the first subset.
